January 9, 2023 1:49pm
Day#1 ... so far:
Ionis Pharmaceuticals (IONS), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), BioLife Solutions (BLFS), MiMedx (MDXG), Solid Biosciences (SLDB), AxoGen (AXGN), bluebird bio (BLUE), Prime Medicine (PRME), Beam Therapeutics (BEAM), Alnylam Pharmaceuticals (ALNY), Sage therapeutics (SAGE)
Some updates …
Ionis Pharmaceuticals (IONS -$1.77): Royalty Pharma Plc agreed to pay up to $1.125 billion for drug royalties owned by IONS. The royalties include Ionis' interests in Biogen's Spinraza (nusinersen) medicine and Novartis' pelacarsen.
Editas Medicine (EDIT -$0.63): is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report. In a statement released Monday Editas said the move will extend its cash runway into 2025.
Voyager Therapeutics (VYGR +$7.72): Neurocrine Biosciences (NBIX) and VYGR have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases. Voyager will receive up-front consideration of $175 million, including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following P1 readout.
BioLife Solutions (BLFS +$1.45): announced 2022 fourth quarter and full year preliminary unaudited revenue and introduced 2023 revenue guidance. < https://finance.yahoo.com/news/biolife-solutions-announces-2022-fourth-130500893.html >
MiMedx (MDXG +$0.095): reaffirms Q4 and FY22 Expectations - net sales to be in the ranges of $73 million to $76 million and $266 million to $269 million.
Solid Biosciences (SLDB -$0.05): announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.
AxoGen (AXGN +$0.23): announced preliminary unaudited fourth quarter and full-year 2022 revenue. Q4 revenue is expected to be approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 2021.
bluebird bio (BLUE -$0.18): commercial launch progress, 2023 program milestones and financial outlook. < https://finance.yahoo.com/news/bluebird-bio-provides-commercial-launch-120000801.html >
Prime Medicine (PRME -$0.19): provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023. < https://finance.yahoo.com/news/prime-medicine-announces-recent-progress-120000804.html >
Beam Therapeutics (BEAM -$0.42): reported progress across the company’s hematology, immunology-oncology and genetic disease portfolios and provided updates on anticipated upcoming milestones. < https://finance.yahoo.com/news/beam-therapeutics-reports-progress-across-113000013.html >
Alnylam Pharmaceuticals (ALNY -$4.78): announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches. < https://finance.yahoo.com/news/alnylam-announces-preliminary-fourth-quarter-230000243.html >
Sage Therapeutics (SAGE -$0.53): key updates on programs across Sage’s depression, neuropsychiatry and neurology portfolios. Sage is advancing a portfolio of clinical programs featuring internally discovered novel chemical entities with the potential to become differentiated products designed to improve brain health by targeting the GABAA and NMDA receptor systems. Dysfunction in these systems is thought to be at the core of numerous neurological and neuropsychiatric disorders.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.